Pfizer expands anti-infectives pipeline with acquisition

29 April 2021
pfizer_colour_new_large

US pharma giant Pfizer (NYSE: PFE) said yesterday that it has acquired San Diego-based Amplyx Pharmaceuticals, a privately-held biotech dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

Amplyx’ lead compound, fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. Financial terms of this acquisition were not disclosed.

In addition to fosmanogepix, Pfizer acquires Amplyx' early-stage pipeline, including potential antiviral (MAU868) and antifungal (APX2039) therapies. MAU868, licensed from Novartis (NOVN: VX), is a potent neutralizing monoclonal antibody with activity against the BK virus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology